Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the U.S. MaterniT21 PLUS is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation.
Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international...
From other sites
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
at CNBC.com (Mar 15, 2013)
at CNBC.com (Apr 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs